Related Experiment Video
Updated: Jul 21, 2026
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
In Silico Identification and In Vitro Validation of Repurposed Compounds Targeting the RSV Polymerase
Eric Xu1, Seohyun Park1, Juan Calderon1
1Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.
Insights
Researchers identified Micafungin as a promising drug candidate against Respiratory Syncytial Virus (RSV). This antifungal medication effectively inhibits the essential RSV RNA-dependent RNA Polymerase (RdRP), offering new hope for treating this common infant respiratory illness.
Area of Science:
- Virology
- Drug Discovery
- Computational Chemistry
Background:
- Respiratory Syncytial Virus (RSV) is a leading cause of infant hospitalization worldwide.
- Currently, no effective treatments exist for RSV infections.
- The RSV RNA-dependent RNA Polymerase (RdRP) is a critical target for antiviral drug development.
Purpose of the Study:
- To identify novel small molecules targeting the RSV RNA-dependent RNA Polymerase (RdRP) using computational analysis.
- To evaluate repurposed drug candidates for their potential as RSV inhibitors.
- To compare the efficacy of identified compounds against existing RSV inhibitors.
Main Methods:
- In silico computational analysis, including molecular docking and protein-ligand simulation, of a 6554-molecule database.
- Evaluation of 18 small molecules from previous studies.
- In vitro transcription assays to validate compound inhibition of RSV RdRP.
Main Results:
- Ten repurposed compound candidates were identified against the RSV polymerase.
- Micafungin, an antifungal medication, demonstrated significant inhibition and improved binding affinity compared to current inhibitors like ALS-8112 and Ribavirin.
- In vitro assays confirmed Micafungin's ability to inhibit RSV RdRP activity.
Conclusions:
- Micafungin shows significant potential as an effective antiviral agent against RSV.
- These findings advance RSV drug development and suggest potential for broad-spectrum antivirals targeting non-segmented negative-sense (NNS) RNA viral polymerases.
- The study highlights the utility of computational approaches in identifying repurposed drugs for viral infections.
Abstract:
Respiratory Syncytial Virus (RSV) is the top cause of infant hospitalization globally, with no effective treatments available. Researchers have sought small molecules to target the RNA-dependent RNA Polymerase (RdRP) of RSV, which is essential for replication and transcription. Based on the cryo-EM structure of the RSV polymerase, in silico computational analysis including molecular docking and the protein-ligand simulation of a database, including 6554 molecules, is currently undergoing phases 1-4 of clinical trials and has resulted in the top ten repurposed compound candidates against the RSV polymerase, including Micafungin, Totrombopag, and Verubecestat. We performed the same procedure to evaluate 18 small molecules from previous studies and chose the top four compounds for comparison. Among the top identified repurposed compounds, Micafungin, an antifungal medication, showed significant inhibition and binding affinity improvements over current inhibitors such as ALS-8112 and Ribavirin. We also validated Micafungin's inhibition of the RSV RdRP using an in vitro transcription assay. These findings contribute to RSV drug development and hold promise for broad-spectrum antivirals targeting the non-segmented negative-sense (NNS) RNA viral polymerases, including those of rabies (RABV) and Ebola (EBOV).
